Indication

Schizophrenia

RAG rating

Amber initiation

Document type

Decision document

Place

Hertfordshire and West Essex ICB

Output type

Pharmacy / Prescribing

Document

Download

Lurasidone

 

HERTFORDSHIRE AND WEST ESSEX AREA PRESCRIBING COMMITTEE (HWE APC)

 

Lurasidone for schizophrenia

AMBER INITIATION

Recommended for initiation by specialist, ongoing prescribing in primary care.

Name generic (trade) Lurasidone

What it is Second-generation (atypical) antipsychotic

Indication Licensed for the treatment of schizophrenia in adults and adolescent aged 13 years and over.

Date decision last revised September 2022

Decision status Final

NICE / SMC Guidance SMC: accepted for restricted use AWMSG: recommended as an option for treatment of schizophrenia.

HWE APC recommendation:

Lurasidone is recommended with an Amber Initiation status for use within its licensed indication (i.e. for schizophrenia) for adult patients (aged 18 years and over) once aripiprazole has either failed to manage the patient’s condition or is not suitable due to a contraindication or intolerance. Initiation, clinical stabilisation (assessment of efficacy and side effects) and dose stabilisation to be carried out by specialist (usually at least 3 months), with continuation in primary care.

Review date: The recommendation is based upon the evidence available at the time of publication. This recommendation will be reviewed upon request in the light of new evidence becoming available.